These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 15967003

  • 1. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 2. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM, Gil-Vernet S, Seron D, Hueso M, Fulladosa X, Cruzado JM, Moreso F, Fernandez A, Torras J, Riera L, Castelao AM, Alsina J.
    Nephrol Dial Transplant; 1998 Oct 27; 13(10):2601-4. PubMed ID: 9794567
    [Abstract] [Full Text] [Related]

  • 9. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J, Arns W, Marti HP, Hauss J, Ketteler M, Beckurts T, Boesmueller C, Pohanka E, Martin PY, Gerhardt M, Farese S, Neumayer HH, Floege J, Gurr C, Budde K, DACH Study Group.
    Nephrol Dial Transplant; 2010 Jan 27; 25(1):283-92. PubMed ID: 19773417
    [Abstract] [Full Text] [Related]

  • 10. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 11. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B.
    Transplantation; 2001 May 15; 71(9):1282-7. PubMed ID: 11397963
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F.
    Clin Transplant; 2003 Dec 15; 17(6):511-7. PubMed ID: 14756266
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
    Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Caravaggio C, Vasquez AR, Halloran P.
    Transplantation; 2001 Sep 15; 72(5):845-50. PubMed ID: 11571448
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J.
    Clin Transplant; 2008 Sep 15; 22(2):200-10. PubMed ID: 18339140
    [Abstract] [Full Text] [Related]

  • 19. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D, Cantarovich M, Cecere R, Giannetti N.
    Clin Transplant; 2004 Oct 15; 18(5):493-6. PubMed ID: 15344949
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR, Moudgil A, Vo A, Jordan SC.
    Am J Health Syst Pharm; 2005 Feb 15; 62(4):391-6. PubMed ID: 15745891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.